Сirculating DNA markers for assessing antitumor therapy efficacy and monitoring metastatic colorectal cancer
Introduction: Colorectal cancer remains one of the leading causes of oncological morbidity and mortality. Aberrant methylation patterns of tumor-suppressor genes and oncogenes have been detected in circulating DNA isolated from the blood of cancer patients, suggesting their potential utility as diagnostic and prognostic markers.
Objective: To evaluate changes in the methylation levels of VIM, SEPTIN9, and DCC genes in cell-surface-bound cell-free DNA (csb-cfDNA) from the blood of metastatic colorectal cancer (mCRC) patients after antitumor treatment over a long-term follow-up period.
Methods: Blood samples were collected from mCRC patients (n = 21) at baseline, after three courses of preoperative chemotherapy (FOLFOXIRI regimen), 10–15 days post-surgery, and every three months during follow-up. The methylation levels of VIM, SEPTIN9, and DCC genes were quantified by methylation-specific polymerase chain reaction.
Results: Preoperative chemotherapy and tumor resection were each associated with a significant decrease in SEPTIN9 and VIM methylation levels in csb-cfDNA compared to baseline (2.3-fold and 2.0-fold, respectively; p ≤ 0.05). DCC methylation decreased 1.5-fold after surgery relative to pre-treatment levels (p ≤ 0.05). During follow-up after completion of combined treatment, methylation levels of SEPTIN9, VIM, and DCC remained stable in mCRC patients without signs of disease progression (n = 8), showing no significant change from post-surgical values (days 10–15). In contrast, mCRC patients with disease progression (n = 13) exhibited increased methylation levels of SEPTIN9, VIM and DCC compared to post-resection values.
Conclusion: These findings indicate that monitoring VIM, DCC, and SEPTIN9 methylation levels in csb-cfDNA has potential for evaluating the effectiveness of antitumor therapy and for early detection of relapses in mCRC patients during the follow-up period.
- Bediako-Bowan AAA, Naalane N, Dakubo JCB. Morbidity and oncological outcomes after intersphincteric resection of the rectum for low-lying rectal cancer: experience of a single center in a lower-middle-income country. BMC Surg. 2023;23:39. doi: 10.1186/s12893-023-01940-9
- Schrag D, Shi Q, Weiser MR, et al. Preoperative Treatment of Locally Advanced Rectal Cancer. N Engl J Med. 2023;389:322-334. doi: 10.1056/NEJMoa2303269
- Dobrodeev AY, Afanasyev SG, Tarasova AS, et al. Short-term outcomes of preoperative chemotherapy in patients with upper ampullary rectal cancer. Siberian J Oncol. 2021;20:23-31. doi: 10.21294/1814-4861-2021-20-6-23-31
- Szilágyi M, Pös O, Márton É, et al. Circulating Cell-Free Nucleic Acids: Main Characteristics and Clinical Application. Int J Mol Sci. 2020;21:6827. doi: 10.3390/ijms21186827
- Dai X, Ren T, Zhang Y, et al. Methylation multiplicity and its clinical values in cancer. Expert Rev Mol Med. 2021;23:1-10. doi: 10.1017/erm.2021.4
- Ghadiri Moghaddam F, Farajnia S, Karbalaei-Mahdi M, et al. Epigenetic insights in the diagnosis, prognosis, and treatment selection in CRC, an updated review. Mol Biol Rep. 2022;49:10013-10022. doi: 10.1007/s11033-022-07569-w
- Ponomaryova AA, Rykova EY, Solovyova AI, et al. Genomic and Transcriptomic Research in the Discovery and Application of Colorectal Cancer Circulating Markers. Int J Mol Sci. 2023;24:12407. doi: 10.3390/ijms241512407
- Vagionas A, Balgkouranidou I, Koukaki T, et al. Prognostic significance of SOX17 and WNT5a promoter methylation status in circulating cell-free DNA metastatic colorectal cancer patients. Hippokratia. 2023;27(1):7-11.
- Raunkilde L, Hansen TF, Andersen RF, et al. NPY Gene Methylation in Circulating Tumor DNA as an Early Biomarker for Treatment Effect in Metastatic Colorectal Cancer. Cancers (Basel). 2022;14:4459. doi: 10.3390/cancers14184459
- Doleschal B, Kirchweger P, Schwendinger S, et al. Response prediction by mutation- or methylation-specific detection of ctDNA dynamics in pretreated metastatic colorectal cancer. Ther Adv Med Oncol. 2023;15:17588359231200462. doi: 10.1177/17588359231200462
- Barták BK, Fodor T, Kalmár A, et al. Liquid Biopsy-Based Approach for Monitoring Treatment Response in Post-Operative Colorectal Cancer Patients. Int J Mol Sci. 2022;23:3774. doi: 10.3390/ijms23073774
- Chen ZG, Ji XM, Xu YX, et al. Methylated ctDNA predicts early recurrence risk in patients undergoing resection of initially unresectable colorectal cancer liver metastases. Ther Adv Med Oncol. 2024;16:17588359241230752. doi: 10.1177/17588359241230752
- Ponomaryova AA, Rykova EY, Solovyova AI, et al. Dynamic Changes in Circulating Methylated Markers in Response to Antitumor Therapy of Rectal Cancer. J Gastrointest Cancer. 2024;55:1190-1198. doi: 10.1007/s12029-024-01066-y
- Ponomaryova AA, Rykova EY, Azhikina TL, et al. Long interspersed nuclear element-1 methylation status in the circulating DNA from blood of patients with malignant and chronic inflammatory lung diseases. Eur J Cancer Prev. 2021;30(2):127-131. doi: 10.1097/CEJ.0000000000000601
- Jin S, Zhu D, Shao F, et al. Efficient detection and post-surgical monitoring of colon cancer with a multi-marker DNA methylation liquid biopsy. Proc Natl Acad Sci USA. 2021;118:e2017421118. doi: 10.1073/pnas.2017421118
- Wang YH, Chang SC, Ansar M, et al. Eps15 Homology Domain-Containing Protein 3 Hypermethylation as a Prognostic and Predictive Marker for Colorectal Cancer. Biomedicines. 2021;9:453. doi: 10.3390/biomedicines9050453
- Huang M, He J, Lai W, et al. Methylated septin 9 gene is an important prognostic marker in stage II and stage III colorectal cancer for evaluating local recurrence or distant metastasis after surgery. BMC Gastroenterol. 2022;28;22:87. doi: 10.1186/s12876-022-02172-6
- Yuan RQ, Zhao H, Wang Y, et al. SEPTIN9-SDC2-VIM methylation signature as a biomarker for the early diagnosis of colorectal cancer. Am J Cancer Res. 2022;12:3128-3140.
- Liu Y, Ming H, Xu L, et al. DNA methylation analysis of the SDC2, SEPT9 and VIM genes in fecal DNA for colorectal cancer diagnosis. BMC Cancer. 2024;24:1205. doi: 10.1186/s12885-024-12990-4
- Aslam MS, Shaeer A, Abbas Z, et al. Cell-Free DNA Quantification and Methylation Status of DCC Gene as Predictive Diagnostic Biomarkers of Lung Cancer in Patients Reported at Gulab Devi Chest Hospital, Lahore. Technol Cancer Res Treat. 2017;16:758-765. doi: 10.1177/1533034616682155
- Gopal P, Ahmed Z, Venkata Ravi Kant V, et al. Circulating tumor DNA for monitoring colorectal cancer: A prospective observational study to assess the presence of methylated SEPT9 and VIM promoter genes and its role as a biomarker in colorectal cancer management. Turk J Surg. 2023;39:107-114. doi: 10.47717/turkjsurg.2023.6038
- Vlassov VV, Laktionov PP, Rykova EY. Circulating nucleic acids as a potential source for cancer biomarkers. Curr Mol Med. 2010;10:142-165. doi: 10.2174/156652410790963295
- Ponomaryova AA, Rykova EY, Cherdyntseva NV, et al. Concentration and Distribution of Single-Copy β-Actin Gene and LINE-1 Repetitive Elements in Blood of Lung Cancer Patients. In: Gahan PB, ed. Circulating Nucleic Acids in Plasma and Serum. Dordrecht, Netherlands: Springer; 2011:41-45. doi: 10.1007/978-90-481-9382-0_6
- Rykova E, Sizikov A, Roggenbuck D, et al. Circulating DNA in rheumatoid arthritis: pathological changes and association with clinically used serological markers. Arthritis Res Ther. 2017;19:85. doi: 10.1186/s13075-017-1295-z
- Kontic M, Stojsic J, Jovanovic D, et al. Aberrant promoter methylation of CDH13 and MGMT genes is associated with clinicopathologic characteristics of primary non-small-cell lung carcinoma. Clin Lung Cancer. 2012;13:297-303. doi: 10.1016/j.cllc.2011.11.003
- Ponomaryova A, Rykova E, Cherdyntseva N, et al. Potentialities of aberrantly methylated circulating DNA for diagnostics and post-treatment follow-up of lung cancer patients. Lung Cancer. 2013;81:397-403. doi: 10.1016/j.lungcan.2013.05.016
- Gainetdinov IV, Kapitskaya KY, Rykova EY, et al. Hypomethylation of human-specific family of LINE-1 retrotransposons in circulating DNA of lung cancer patients. Lung Cancer. 2016;99:127-130. doi: 10.1016/j.lungcan.2016.07.005
- Tamkovich S, Tupikin A, Kozyakov A, et al. Size and Methylation Index of Cell-Free and Cell-Surface-Bound DNA in Blood of Breast Cancer Patients in the Contest of Liquid Biopsy. Int J Mol Sci. 2022;23(16):8919. doi: 10.3390/ijms23168919